Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA versus OXYMORPHONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA versus OXYMORPHONE HYDROCHLORIDE.
NUCYNTA vs OXYMORPHONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
Oxymorphone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception and response. It also has affinity for kappa and delta opioid receptors.
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
Initial: 1 mg IV/IM every 3-4 hours as needed for moderate to severe pain; titrate to effect. For patient-controlled analgesia (PCA), 0.5 mg IV loading dose, then 0.25-0.5 mg every 6-15 minutes with lockout. Rectal suppository: 5 mg every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals.
Terminal elimination half-life: 7-9 hours (range 4-12 h in elderly/renal impairment). Clinically, steady-state achieved within 24-36 hours.
Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces).
Primarily renal (90% as parent drug and metabolites); <1% fecal. Unchanged oxymorphone accounts for ~30% of urinary recovery.
Category C
Category C
Opioid Analgesic
Opioid Analgesic